Regencell Bioscience Limited (RGC) saw its shares surge 28.22% in pre-market trading on Tuesday, continuing an extraordinary rally that has seen the stock skyrocket by over 46,000% year-to-date. This latest jump comes on the heels of the company's 38-for-1 forward stock split, which took effect on Monday, triggering increased trading activity and investor interest.

The stock split, announced on June 2, provided shareholders of record as of June 12 with 37 additional shares for every share held. Regencell stated that the split was intended to enhance market liquidity and make shares more accessible to investors. However, market observers urge caution, as the company's meteoric rise appears to be driven largely by speculative trading rather than fundamental developments.

Despite its massive market valuation of nearly $30 billion, Regencell Bioscience, a biotech firm focusing on traditional Chinese medicine-based treatments for neurological disorders, has yet to generate any revenue or turn a profit. The company reported a net loss of $4.4 million for its fiscal year ending June 2024. The extreme volatility in the stock price, including multiple trading halts due to circuit breakers, highlights the risks associated with such speculative movements and raises questions about the sustainability of its current valuation.